IMMP Stock: Immutep Limited Stock Price, Analysis & Insights
Get live immp stock price $2.70, comprehensive Immutep Limited stock analysis, charts, news, and expert forecast. Real-time immp stock data and investment insights.
Loading chart...
Company Overview
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Company Information
- CEO
- Marc Voigt
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 41
Contact Information
- Website
- https://www.immutep.com
- Address
- Australia Square
- Country
- AU
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.84)
Business Model & Strategy
Immutep Limited operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Marc Voigt, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Immutep Limited competes in the Biotechnology within the broader Healthcare. With 397.4 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Market, Immutep Limited provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Immutep Limited should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Immutep Limited shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Immutep Limited
- ⚠Investors should consider how Immutep Limited fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
397.42M
P/E Ratio
-7.30
Beta
1.84
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 397.42M market capitalization
- Trading Volume: 623.31K shares traded today
- Price Range: 52-week range of $1.32 - $3.53
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Immutep Limited
Immutep Limited (IMMP) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 397.42M, the company represents a significant player in its market. The stock is currently trading at $2.70 with a positivedaily change of 8.43%.
The company's 41 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -7.30, beta of 1.84, and 52-week price range from $1.32 to $3.53when evaluating investment opportunities.
Why Invest in Immutep Limited?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Marc Voigt
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.